Is Safeguard Scientifics, Inc. overvalued or undervalued?

As of 1 October 2023, Safeguard Scientifics, Inc. has moved from a fair to an attractive rating. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.5, and a return on equity of 12%.
In comparison to its peers, such as BioScrip, Inc. with a price-to-earnings ratio of 18.5 and Acorda Therapeutics, Inc. at 16.0, Safeguard's lower valuation suggests it is trading at a discount relative to the market. Additionally, the stock's recent performance has outpaced the Sensex, reinforcing the notion of undervaluation.